MediWound Ltd. (MDWD)
MDWDNASDAQ-GM Medicinal Chemicals and Botanical Products
$14.37
+0.2900 (+2.06%) today
Regular session, Nov 10, 3:15 PM ET
- Market cap
- $206.79m
- P/E
- –
- EPS, last 4 quarters
- $-1.80
- Dividend yield
- –
- Day range
- $13.97 to $14.41
- 52-week range
- $11.80 to $19.70
- Average volume
- 108.8k
- Previous close
- $14.08
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $29.60, +106.0% from here
Earnings
next estimate $-0.6600Next report Nov 12, 2026
Sep 2025
+70.4%
Dec 2025
+13.8%
Mar 2026
+64.6%
Jun 2026
-1.3%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue EstimatesZacks · 1 day ago
- MediWound Ltd. Enters Underwriting Agreement for $17.25 million Public OfferingFintel · 5 days ago
- Cronos Group (CRON) Q3 Earnings and Revenues Beat EstimatesZacks · 5 days ago
- MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?Zacks · 5 days ago
- MediWound Prices $15 Mln Offering Of Shares At $12.50 Per Share; Stock Down RTTNews · 7 days ago
- Madrigal (MDGL) Q3 Earnings and Revenues Beat EstimatesZacks · Nov 3, 2026
- MediWound's EscharEx Phase III VALUE Study To Continue Without Modification Following DSMB Review RTTNews · Sep 14, 2026
- Mediwound Becomes Oversold (MDWD)BNK Invest · Aug 26, 2026
The company
MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for tissue repair. The company's FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound's late-stage development candidate, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with the potential to become a new standard of care in wound management.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ-GM
- Region
- Middle East
- Website
- mediwound.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.